No buy transactions available for this period
Gilead Sciences, Inc. filed its 13F report for Q4 2025 on February 12, 2026. The portfolio totaled 1.94 B reflecting a +8.04% change from the prior quarter, spanning 6 assets. The top 10 holdings comprised 100.0% of the portfolio, with Financials as the largest sector allocation. Quarterly activity included 0 new positions and 3 complete exits.
Items:
Total Value:
| Issuer Name | Class | Value | Shares | Option Type |
|---|
Gilead Sciences submitted their Form 13F-HR for the Q4 2025 period on 02/12/2026. This was the only submission for the quarter.
In the Q4 2025 filing, Gilead Sciences reported a managed portfolio value of 1.94 B, consisting of 6 individual positions.
This page displays the raw filing documents. To see which stocks Gilead Sciences bought or sold during Q4 2025, please visit Gilead Sciences's Portfolio Analysis page.